Postmenopausal Vaginal Atrophy Pva Drugs Market Forecast

Postmenopausal Vaginal Atrophy PVA Drugs Single User License:

Market - Global Industry Analysis, Size, Share, USD 4315.5

Growth, Trends and Forecast 2015 - 2023

 Flat 10% Discount!!







Transparency Market Research

State Tower,

90, State Street, Suite 700.

Albany, NY 12207

United States

www.transparencymarketresearch.com

sales@transparencymarketresearch.com

Free Customization as per your requirement

You will get Custom Report at Syndicated Report

price

Report will be delivered with in 15-20 working days

Request Sample

Buy Now

REPORT DESCRIPTION

Postmenopausal Vaginal Atrophy (PVA) refers to decrease in estrogen production most commonly after menopause and the condition is also

called as vaginal Atrophy. Less estrogen leads to drying, thinning, and decreased elasticity of vaginal tissues. Various other causes leading to

decrease in estrogen levels include perimenopause, during breast feeding, surgical menopause, pelvic radiation therapy and chemotherapy and

also as a side effect of breast cancer hormonal treatment. Symptoms of vaginal Atrophy include burning, redness, itching, dyspareuia, and

irritation. Vaginal atrophy is a common result of the treatment of many gynecological cancers. Postmenopausal vaginal Atrophy is known to occur

commonly due to increase in life expectancy and lengthening of average lifespan post menopause. Diagnosis for PVA includes pelvic examination,

vaginal smear test, vaginal activity test, blood test and urine test.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/postmenopausal-vaginal-atrophy-pva-drugs-market.html

The treatment generally involves use of hormonal replacement therapy, estrogen creams, pessaries or lubricating gels. The sensitivity of

urogenital tract to the decline in estrogen levels leads to symptoms related to vaginal atrophy, and is also known to affect sexual function and

quality of life in about half of all postmenopausal women. Most commonly, vaginal atrophy becomes evident 4–5 years...